"The compound 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropane carboxamido)-3-methylpyridin-2-yl)benzoic acid in salt form is disclosed in International PCT Publication WO 2007056341 (said publication being incorporated herein by reference in its entirety) as a modulator of CFTR activity and thus as a useful treatment for CFTR-mediated diseases such as cystic fibrosis. Form I of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-- methylpyridin-2-yl)benzoic acid ('Compound 1, Form I'), which is a substantially crystalline and salt-free form, is disclosed in U.S. patent application Ser. No. 12/327,902, filed
In addition to obtaining background information on this patent, NewsRx editors also obtained the inventors' summary information for this patent: "The present invention relates to solid polymorphic forms of the compound 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-- methylpyridin-2-yl)benzoic acid (hereinafter 'Compound 1') which has the structure below:
"Polymorphism is a known phenomena for solid forms of compounds. The physical characteristics of polymorphs are known to affect, for example, solubility, rate of dissolution, flow properties, rate of absorption, and stability. Hence, choice of a particular polymorph is important in the development and preparation of compositions.
"In one embodiment, Compound 1 is in solvated form, designated herein as 'Compound 1, Solvate Form A.' In one embodiment, the solvate form is Compound 1, Methanol Solvate Form A. In another embodiment, the solvate is Compound 1, Ethanol Solvate Form A. Other embodiments include:
"Compound 1, Acetone Solvate Form A;
"Compound 1, 2-Propanol Solvate Form A;
"Compound 1, Acetonitrile Solvate Form A;
"Compound 1, Tetrahydrofuran Solvate Form A;
"Compound 1, Methyl Acetate Solvate Form A;
"Compound 1, 2-Butanone Solvate Form A;
"Compound 1, Ethyl Formate Solvate Form A; and
"Compound 1, 2-Methyltetrahydrofuran Solvate Form A.
"In still another aspect, Compound 1 is in a salt form. The salt form is referred to as 'Compound 1, HCl Salt Form A'.
"The Compound 1 solid forms disclosed herein and pharmaceutical compositions thereof are useful for lessening the severity of CFTR-mediated diseases such as, for example, cystic fibrosis. The Compound 1 solid forms can be used to prepare other Compound 1 solid forms, as well as pharmaceutical compositions comprising Compound 1 solid forms, using the processes disclosed herein."
For more information, see this patent: Keshavarz-Shokri, Ali; Zhang, Beili; Krawiec, Mariusz. Solid Forms of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl)benzoic Acid. U.S. Patent Number 8507687, filed
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- Grizzly Bears Could Be Taken Off Endangered List
- Ford Plans New Cars, Jobs in 2014
- 'Rape Insurance' Bill Passes in Michigan
- Hawaii Official Who Release Obama Certificate Only Victim of Plane Crash
- Gold, Silver Slide on Prospects of Fed Exit
- Ted Cruz Coloring Book Selling Briskly
- Boehner Lashes Out Against Ted Cruz, Far Right
- Kim Jong Un's Uncle Executed
- TFA Recruiting DACA Recipients
- Podesta Likely to Reject Keystone XL